期刊文献+

雷帕霉素在慢性肾脏疾病治疗中的应用

Application of rapamycin to the treatment for chronic kidney diseases
原文传递
导出
摘要 近年有不少新型免疫抑制剂问世,如吗替麦考酚酯、来氟米特、他克莫司及西罗莫司等,除来氟米特外,上述各药均是先用于器官移植抗免疫排斥反应,而后才扩展至内科免疫介导性疾病包括某些肾脏病治疗。国内、外的临床应用经验显示,上述新型免疫抑制剂确为这些肾脏病治疗增添了更多武器,提高了疾病缓解率,所以本刊特在此组织专题笔谈,与读者分享有关研究成果。但是,在临床具体应用时,临床医师必须深入了解上述各药副反应,避免严重不良反应发生。而且,目前我国国家食品药品监督管理局也还未批准这些药的肾脏病治疗适应证,也提醒临床应用时引起注意。
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2008年第5期327-329,共3页 Chinese Journal of Practical Internal Medicine
关键词 慢性肾脏疾病 雷帕霉素 chronic kidney disease rapamycin
  • 相关文献

参考文献14

  • 1Buhaescu I,Izzedine H,Covic A, Sirolimus- challenging current perspectives[J]. Ther Drug Monlt,2006,28(5 ) :577 -584.
  • 2张国娟,李航,李学旺.雷帕霉素对炎性反应状态下肾小球系膜细胞内脂质稳态的影响[J].中华肾脏病杂志,2007,23(12):789-794. 被引量:5
  • 3Bonegio RG, Fuhro R, Wang Z, et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy [ J ]. J Am Soc Nephrol, 2005,16 ( 7 ) :2063 - 2072.
  • 4Naumovic R,Jovovic D, Basta-Jovanovic G, et al. Effects of rapamycin on active Heymann nephritis [ J ]. Am J Nephrol, 2007,27 (4) :379 -389.
  • 5Wu MJ,Wen MC,Chiu YT. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis [ J ]. Kidney Int, 2006,69 ( 11 ) :2029 -2036.
  • 6Diekmann F, Rovira J, Carreras J, et al. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass [ J ]. J Am Soc Nephrol, 2007,18 ( 10 ) : 2653 - 2360.
  • 7Rangan GK, Coombes JD. Renoprotective effects of sirolimus in non-immune initiated focal segmental glomerulosclerosis [ J ]. Nephrol Dial Transplant ,2007,22 ( 8 ) :2175 - 2182.
  • 8Yang Y,Wang J, Qin L, et al. Rapamycin prevents early steps of the development of diabetic nephropathy in rats [ J ]. Am J Nephrol,2007,27(5 ) :495 -502.
  • 9Alperovich G, Rama I, Lloberas N, et al. New immunosuppresor strategies in the treatment of murine lupus nephritis [J]. Lupus, 2007,16(1) :18 -24.
  • 10Ramos-Barran A, Pinera-Haces C, Gomez-Alamillo C, et al. Prevention of murine lupus disease in (NZBxNZW) F1 mice by sirolimus treatment [ J ]. Lupus, 2007,16 ( 10 ) :775 - 781.

二级参考文献22

  • 1陈文祥 李培英 王抒等.高效液相色谱法测定血清胆固醇的研究:一种新参考方法的建议[J].中华医学检验杂志,1993,16:146-146.
  • 2Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: systematic review and meta-analysis of randomized trials. Transplantation, 2006, 81 : 1234-1248.
  • 3Elloso MM, Azrolan N, Sehgal SN, et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant, 2003, 3: 562- 569.
  • 4Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl, 1991, 31: S29-S34.
  • 5Moorhead JF, Chan MK, E1-Nahas M, et al. Lipid nephrotoxicity in chronic progressive glomerular and tubulo- interstitial disease. Lancet, 1982, 2: 1309-1311.
  • 6Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol, 2004, 24: 46- 53.
  • 7Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo), 1975, 28: 727-732.
  • 8Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem, 1998, 31: 335-340.
  • 9Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation, 2001, 104: 852-855.
  • 10Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation, 2002, 74: 1070-1076.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部